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Rodrigues SC, Pantaleão LC, Nogueira TC, Gomes PR,
Albuquerque GG, Nachbar RT, Torres-Leal FL, Caperuto LC,
Lellis-Santos C, Anhê GF, Bordin S. Selective regulation of
hepatic lipid metabolism by the AMP-activated protein kinase
pathway in late-pregnant rats. Am J Physiol Regul Integr Comp
Physiol 307: R1146 –R1156, 2014. First published September 1,
2014; doi:10.1152/ajpregu.00513.2013.—The liver plays an essen-
tial role in maternal metabolic adaptation during late pregnancy. With
regard to lipid metabolism, increased secretion of very low-density
lipoprotein (VLDL) is characteristic of late pregnancy. Despite this
well-described metabolic plasticity, the molecular changes underlying
the hepatic adaptation to pregnancy remain unclear. As AMPK is a
key intracellular energy sensor, we investigated whether this protein
assumes a causal role in the hepatic adaptation to pregnancy. Pregnant
Wistar rats were treated with vehicle or AICAR (5-aminoimidazole-
4-carboxamide ribonucleotide) for 5 days starting at gestational day
14. At the end of treatment, the rats were subjected to an intraperito-
neal pyruvate tolerance test and in situ liver perfusion with pyruvate.
The livers were processed for Western blot analysis, quantitative
PCR, thin-layer chromatography, enzymatic activity, and glycogen
content measurements. Blood biochemical profiles were also assessed.
We found that AMPK and ACC phosphorylation were reduced in the
livers of pregnant rats in parallel with a reduced level of hepatic
gluconeogenesis of pyruvate. This effect was accompanied by both a
reduction in the levels of hepatic triglycerides (TG) and an increase in
circulating levels of TG. Treatment with AICAR restored hepatic
levels of TG to those observed in nonpregnant rats. Additionally,
AMPK activation reduced the upregulation of genes related to VLDL
synthesis and secretion observed in the livers of pregnant rats. We
conclude that the increased secretion of hepatic TG in late pregnancy
is concurrent with a transcriptional profile that favors VLDL produc-
tion. This transcriptional profile results from the reduction in hepatic
AMPK activity.
pregnancy; liver; AMPK; lipid metabolism; very low-density lipopro-
tein
THE THIRD GESTATIONAL PERIOD is a physiological state of insulin
resistance that, in normal pregnancies, lasts until the delivery
(2, 13). Insulin resistance in glycolytic skeletal muscle fibers
plays an important role in the reduced glucose clearance during
pregnancy (33). However, the whole body maternal insulin
resistance is compensated by an increase in -cell mass and
insulin secretion, which are also promptly reset after delivery
(3, 11, 32, 44).
The nature of the metabolic changes associated with preg-
nancy that occur in the liver, including whether they are
connected to hepatic insulin resistance, remains a matter of
controversy. Some studies have reported that pregnancy is
associated with an impairment of the insulin-induced suppres-
sion of hepatic glucose production (52) and reduced insulin
receptor activation (40), whereas other works have reported
increased hepatic insulin sensitivity mediated by the upregula-
tion of tyrosine phosphorylation of insulin receptor substrate-1
in the liver (25). Moreover, in humans, there is a consensus that
hepatic glucose production remains insulin-sensitive through-
out normal pregnancy but is insulin-resistant in gestational
diabetes (14, 19). In dogs, Connolly et al. (23) have demon-
strated that the reduction in net hepatic glucose output is
similar in pregnant and nonpregnant states, irrespective of
using intermediate or high insulin doses.
As a key metabolic organ, the liver plays an integral role in
energy homeostasis, not only by regulating glucose metabo-
lism, but also by enhancing its production of triglycerides (TG)
that return to the circulation as very low-density lipoproteins
(VLDL) during lipid metabolism. Around parturition, the lipo-
protein lipase in the mammary glands becomes active, which
diverts circulating TG to this organ to ensure proper milk
synthesis (28). Although the metabolic routes underlying this
hepatic adaptation are well defined, the signaling pathways and
transcriptional profile alterations that allow the liver to increase
VLDL synthesis during pregnancy remain unspecified.
AMPK, a serine/threonine kinase, functions as a fuel sensor
in several body tissues, including the liver. A growing body of
evidence indicates that the regulatory role played by AMPK on
hepatic metabolic fluxes correlates with hormone action in the
liver, thus, suggesting that this enzyme may be a functional
mediator of endocrine action during specific physiological
states (26). Glucagon induces ACC phosphorylation and inac-
tivation as a result of increased AMPK activity, which results
in the suppression of lipid biogenesis (57).
Detailed studies have demonstrated the relevance of hepatic
AMPK activity for the regulation of the metabolic demands
during acute or chronic muscular work (15, 18) and fasting-
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refeeding conditions (5, 41); however, the involvement of
hepatic AMPK in maternal lipid metabolism during pregnancy
remains unexplored. In the present study, we aimed to evaluate
the mechanisms involved in liver fuel metabolism during late
pregnancy and focused on the AMPK-dependent regulation of
lipid metabolism.
MATERIALS AND METHODS
Experimental design and animal treatment. Nulliparous Wistar rats
at 8 wk of age were housed in a temperature-controlled room (22 
2°C) with the lights on from 7:00 AM to 7:00 PM; standard chow and
water were available ad libitum. Rats were allowed to acclimate for 2
wk in our animal facility prior to being randomized into three groups:
two groups were destined to breed and one remained nulliparous.
Following habituation, two groups were housed with male rats for 5
days (two females and one male per cage). The concomitant presence
of spermatozoa and estrous cells in a vaginal lavage indicated day 0
of gestation. Pregnant rats were housed separately but remained in
visual, olfactory, and auditory contact with unmated rats (i.e., non-
pregnant) at all times.
Treatment with 5-aminoimidazole-4-carboxamide ribonucleotide
(AICAR; cat. no. 2840; Tocris, Bristol, UK) consisted of a subcuta-
neous injection, 0.5 mg·kg1·day1 diluted in 0.9% NaCl, starting at
day 14 and continuing to day 18 day of pregnancy. Two groups
(pregnant and nonpregnant) received the same volume of vehicle
during five consecutive days. Experiments were conducted on the day
following the end of treatment. All studies were performed according
to the guidelines of the Brazilian College for Animal Experimentation
and approved by the Ethics Committee on Animal Use at the Institute
of Biomedical Sciences, University of São Paulo, São Paulo, Brazil.
Blood sample analysis. Blood samples were collected at 9:00 AM.
from nonfasting animals immediately after euthanasia and before the
removal of liver samples. Glucose, TG, total cholesterol, and HDL
cholesterol (HDL-C) concentrations were measured by colorimetric
methods using commercial kits (Labtest Diagnostica, Minas Gerais,
Brazil). Serum insulin (no. EZRMI-13K; Millipore, Billerica, MA)
and portal plasma glucagon (cat. no. 297–57101, Wako Pure Chem-
ical Industries, Osaka, Japan) concentrations were determined by
ELISA, according to the respective manufacturer’s instructions.
Glycogen content and liver-to-body weight ratio. Liver samples
(300 mg) from nonfasting animals were washed three times with
ice-cold PBS and hydrolyzed with 2 ml of 30% KOH (1 h at 98°C).
Glycogen was precipitated with 0.2 ml of Na2SO4 and 4.5 ml of 95%
ethanol. Samples were then boiled for 15 s and centrifuged at 12,000
g for 15 min. The supernatant was discarded, after which, the pellet
was diluted in warm distilled water. Samples were boiled again with
4.5 ml of 95% ethanol and centrifuged. Again, the supernatant was
discarded, and the pellet was dissolved in warm distilled water.
Glycogen concentration was measured with a colorimetric reaction by
adding 1 ml of each sample, 15 l of phenol solution (800 mg/ml),
and 2 ml of H2SO4, and boiling for 15 min in a water bath. The
absorbance was read at 490 nm.
Animals from each group were set apart to measure the liver-to-
body weight ratio at the moment of euthanasia, i.e., the percentage of
the liver to the body weight.
Maximal enzyme activity of de novo fatty acid synthesis. The
activities of malic enzyme (EC 1.1.1.39) and glucose-6-phosphate
dehydrogenase (G6PDH) (EC 1.1.1.49) were analyzed in liver and
adipose tissue (subcutaneous and perigonadal depots) from nonfasting
animals. For this analysis, liver and adipose tissue samples (300 mg)
were processed as previously described (21). Enzyme activities were
expressed as nanomoles per minute per milligram of protein.
Intraperitoneal pyruvate tolerance test (ipPTT). Fasted rats (12 h)
were anesthetized (sodium thiopental, 40 mg/kg) and subjected to an
intraperitoneal injection containing sodium pyruvate solution (250
mg/ml) at a dosage of 2 g/kg. Glucose levels were determined in blood
collected from the tail before (0 min) and 15, 30, 60, 90, and 120 min
after an intraperitoneal pyruvate injection. The area under the curve
(AUC) of glycemia vs. time was calculated using each individual
baseline (basal glycemia) to estimate glucose production after a
pyruvate load.
In situ liver perfusion with pyruvate. Fasted rats (12 h) were
anesthetized and subjected to liver perfusion following the protocol
described previously (24). In brief, rats were submitted to a laparot-
omy, and the livers were perfused with a warmed (37°C) and oxy-
genated perfusion buffer (Krebs-Henseleit bicarbonate buffer without
glucose) via the portal vein. The effluent was collected by a cannula
inserted into the infrahepatic segment of the cava vein. The perfusion
was performed in an open system without recirculation of the perfus-
ate. Livers were initially subjected to a preperfusion (20 min), fol-
lowed by a 10-min perfusion when samples of the effluent fluid were
collected at six different times (i.e., 10, 8, 6, 4, 2, and 1
min). Next, sodium pyruvate (5 mM) was added to the perfusion
buffer, and the livers were perfused for an additional 40 min. During
this interval, samples of the effluent perfusion fluid were collected at
0, 5, 10, 15, 20, 25, 30, 35, and 40 min after commencing the pyruvate
perfusion.
Livers were removed and weighed after the perfusion period. The
glucose concentration of the samples was measured (In Vitro Diag-
nostica Ltda, Distrito Industrial, MG, Brazil), and glucose production
rates were expressed per liver mass (mol·min1·g1) and plotted vs.
time. The AUC during the perfusion with sodium pyruvate was
Table 1. List of primer sets
Gene Forward primer (5=-3=) Reverse primer (5=-3=)
apoB CTGCGGTGGCAGAAATAACG CCTTGAGCAAACCTTAGGTAGGG
cd36 TCTTCCAGCCAACGCCTTTGC TGCACTTGCCAATGTCCAGCAC
dgat1 CAGACCAGCGTGGGCG GAACAAAGAGTCTTGCAGACGATG
dgat2 AAGCCCATCACCACCGTTG TTCCTTCCAGGAGCTGGCAC
fasn TGGTGAAGCCCAGAGGGATC CACTTCCACACCCATGAGCG
g6pc ACCTTCTTCCTGTTTGGTTTCGC CGGTACATGCTGGAGTTGAGGG
mttp TATGACCGTTTCTCCAAGAGTGG TCAAGGTTCTCCTCTCCCTCATC
pck1 AATGATGACCGTCTTGCTTTCG TGGTCTGGACTTCTCTGCCAAG
sec22b CGTGCTCGGAGAAATCTCGG AACACGGCTACTGCTGCAAGC
stk11 AGCATGACCGTAGTGCCCTACC GCCATTCACACAAACAGCCTTG
rpl37a CAAGAAGGTCGGGATCGTCG ACCAGGCAAGTCTCAGGAGGTG
Gene abbreviations and accession numbers are: apoB (NM_019287), apolipoprotein B; cd36 (AF072411), fatty acid translocase/CD36; dgat (NM_053437;
NM_001012345), diacylglycerol O-acyltransferase; fasn (NM_017332), fatty acid synthase; g6pc (NM_013098), glucose-6-phosphatase, catalytic subunit; mttp
(NM_001107727), microsomal triglyceride transfer protein; pck1 (NM_198780), phosphoenolpyruvate carboxykinase 1; sec22b (NM_001025686), vesicle
trafficking protein homolog B; stk11 (NM_001108069), serine/threonine kinase 11/LKB1; rpl37a (X14069), ribosomal protein L37a.
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calculated (mol/g) to estimate the amount of glucose synthesized
from pyruvate relative to the liver mass.
Protein extraction and immunoblotting. Anesthetized nonfasting
rats were euthanized, and a fragment of the liver (100 mg) was
removed and processed for Western blot analysis, as previously
described (45). The primary antibodies used were as follows: an-
tiphosphorylated (p)AMPK (Thr-172) (cat. no. 2535), anti-pACC
(Ser-79) (cat. no. 3661), anti-pCREB (Ser-133) (cat. no. 9191),
anti-CREB (cat. no. 9197), anti-pLKB1 (Ser-428) (cat. no. 3482), and
anti-LKB1 (cat. no. 3047) from Cell Signaling Technology (Danvers,
MA); anti-AMPK-pan (cat. no. 07–181) and anti-ACC (cat. no.
04–322) from Millipore (Billerica, MA); and anti-glucose-6-phospha-
tase- (sc-25840), anti-STAT3 (sc483), and anti-pSTAT3 (Tyr-705)
(sc8059) from Santa Cruz Biotechnologies (Santa Cruz, CA). Anti-
-actin, acquired from Abcam (Cambridge, UK), was used as the
loading control. Secondary antibodies conjugated to horseradish per-
oxidase (Bio-Rad Laboratories, Hercules, CA) were used, followed by
chemiluminescent detection of the bands on X-ray-sensitive films.
Optical densitometry of the films was performed using the Scion
Image analysis software (Scion, Frederick, MD).
RNA extraction and qPCR. Total RNA was extracted from samples
of liver tissue (100 mg) collected from nonfasting animals using
TRIzol reagent, as previously described (45). Extracted RNA was
eluted in RNase-free water, treated with Turbo DNA-free (Ambion,
Austin, TX), according to the manufacturer’s specifications and quan-
tified by spectrophotometry at 260 nm with acceptable 260/280 nm
ratios between 1.8 and 2.0. RNA quality was assessed by ethidium
bromide agarose gel electrophoresis.
For mRNA expression analysis, 1 g of total RNA was reverse
transcribed using Improm-II reverse transcriptase (Promega, Madison,
WI) and random primers, according to the manufacturer’s instruc-
tions. Real-time amplifications were performed using Kapa SYBR fast
DNA polymerase (Kapa Biosystems, Woburn, MA) and following
standard procedures. Values of mRNA expression were normalized to
the internal control gene rpl37a using the CT method. Primer
sequences are in Table 1.
Lipid extraction and thin-layer chromatography. The hepatic lipid
content of nonfasting animals was determined according to methods
described elsewhere (54). Briefly, each sample (200 mg) was
homogenized in methanol:chloroform:PBS solution (1:2:1, vol/vol)
and centrifuged at 15,000 g for 1 min. The upper phase was removed
and reextracted with PBS:chloroform:methanol solution (0.8:1:1, vol/
vol). The lower phase was then reextracted with Folch solution
(chloroform:methanol:water, 3:47:48, vol/vol), and the organic phase
containing the lipid extract was dried (Speed Vac, Savant). The tubes
were frozen with liquid nitrogen and stored at 20°C until chromato-
graphical analysis.
Dried samples were chromatographed using thin-layer chromatog-
raphy with a 250-mm stationary phase of silica gel 60 H and a solvent
system consisting of hexane:diethylic ether:acetic acid (70:30:1, vol/
vol) at 26  2°C. The samples were developed in chloroform:
methanol:water:ammonium hydroxide (25%) (120:75:6:2, vol/vol),
and the plates were visualized in an atmosphere of iodine vapor prior
to scanning and densitometry.
Statistical analysis. All results are presented as the means  SE.
Comparisons were performed using an unpaired Student’s t-test or a
one-way ANOVA, followed by a Tukey-Kramer post hoc testing
when appropriate (INStat, GraphPad Software, San Diego, CA). P
values 	0.05 indicate a significant difference.
RESULTS
Maternal hepatic gluconeogenesis is reduced at the end of
pregnancy. We initially assessed changes in glucose clearance
after in vivo challenge with pyruvate (pyruvate tolerance test)
as an indicator of gluconeogenesis modulation during preg-
nancy. The changes in glucose levels over time after a chal-
lenge with exogenous pyruvate revealed lower mean glucose
levels in pregnant rats when compared with nonpregnant rats.
Significantly lower glucose levels were found at 60, 90, and
120 min after pyruvate challenge. Thus, the AUC obtained
from the curve was reduced in pregnant rats (43% of that in
nonpregnant rats; P 	 0.05) (Fig. 1A).
We next assessed hepatic gluconeogenesis to determine
whether the increased glucose clearance after a pyruvate load
during pregnancy was due to the reduced hepatic conversion of
pyruvate into glucose. An in situ liver perfusion showed that
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Fig. 1. Hepatic gluconeogenesis after pyruvate load is reduced in late-pregnant
rats. Pregnant (gestational day 19) and nonpregnant rats were subjected to an
intraperitoneal pyruvate tolerance test. Glycemia was measured before and 15,
30, 60, 90, and 120 min after sodium pyruvate injection. The area under the
curve (AUC) was calculated for each individual animal within each group (A).
Pregnant and nonpregnant rats were subjected to in situ liver perfusion with
sodium pyruvate. Glucose levels in the perfusate were quantified before (10,
8, 6, 4, 2, 1, and 0 min) and after (5, 10, 15, 20, 25, 30, 35, and 40
min) sodium pyruvate addition to the perfusion buffer. The glucose production
rate was expressed per liver mass (mol·min1·g1) and plotted vs. time. The
AUC during the perfusion with sodium pyruvate was calculated (mol/g) to
estimate the amount of glucose synthesized from pyruvate relative to the liver
mass (B). The results are shown as the means  SE. *P 	 0.05 vs.
nonpregnant group (n 
 4).
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the livers of pregnant rats exhibited reduced rates of glucose
synthesis throughout the period in which pyruvate was present
in the perfusion medium. This result was best observed be-
tween 20 and 30 min after the beginning of perfusion with
pyruvate. The total mass of glucose synthesized from pyruvate
relative to liver weight was also lower in pregnant rats (59% of
that in nonpregnant rats; P 	 0.05) (Fig. 1B).
Changes in hepatic cellular signaling at the end of
pregnancy. The blood glucagon-insulin ratio was assessed in
nonpregnant and late-pregnant rats. As expected, the insulin
levels of pregnant rats were higher than those in nonpregnant
control rats (2.74  0.47 ng/ml vs. 0.85  0.13 ng/ml,
respectively; P 	 0.05), and the glucagon levels were un-
changed (1.63  0.08 ng/ml and 1.75  0.10 ng/ml, respec-
tively). Thus, at this stage of pregnancy, the glucagon-insulin
ratio was significantly decreased in pregnant rats (33% of that
in nonpregnant rats; P 	 0.05) (Fig. 2A).
The cAMP response element binding protein (CREB) is a
transcriptional factor activated by glucagon via PKA-mediated
phosphorylation. In agreement with the glucagon-insulin ratio,
our results showed that CREB phosphorylation was 44% lower
in the livers of pregnant rats than that in the nonpregnant rats
(P 	 0.05; Fig. 2B).
On the other hand, we found increased STAT3 tyrosine
phosphorylation in the livers of pregnant rats (46% higher than
that in nonpregnant rats; P 	 0.05) (Fig. 2C). STAT3 is a
transcription factor that was previously described to bind to
g6pc genes, thereby repressing their transcription (49). G6pc
expression and G6Pase content were reduced in the livers of
pregnant rats (66% and 35% lower, respectively, than nonpreg-
nant rats; P 	 0.05) (Fig. 2, D and E).
Reduced activity of the AMPK signaling pathway in the
livers of pregnant rats. The AMPK content was not signifi-
cantly altered in the livers of pregnant rats, irrespective of
treatment with AICAR (Fig. 3A). AMPK phosphorylation
was reduced in the livers of pregnant rats (25% lower than in
nonpregnant rats; P 	 0.05). Treatment with AICAR restored
AMPK phosphorylation levels in the livers of pregnant rats to
values similar to those of nonpregnant rats (Fig. 3B). The
expression of ACC, a downstream target of AMPK, was not
altered in the livers of pregnant rats or pregnant rats treated
with AICAR (Fig. 3C). Similar to AMPK phosphorylation,
ACC phosphorylation was reduced in the livers of pregnant
rats (41% lower than in nonpregnant rats; P	 0.05). Treatment
with AICAR restored ACC phosphorylation levels in the livers
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Fig. 2. Liver glucagon and STAT3 signaling
correlates with G6Pase expression and gluconeo-
genesis in late pregnancy. Blood glucagon and
insulin levels from pregnant (gestational day 19)
and nonpregnant rats were measured to calculate
the glucagon/insulin ratio (A). Phosphorylated
CREB (B) and STAT3 (C) were analyzed by
immunoblotting liver samples obtained from
pregnant and nonpregnant rats. Phosphorylated
CREB and STAT3 were normalized by their
respective protein contents. These samples were
also used for the analysis of the mRNA expres-
sion of g6pc (D) and the protein content of
G6Pase by immunoblotting (E). G6Pase protein
content was normalized by -actin protein con-
tent. The results are shown as the means  SE.
*P 	 0.05 vs. nonpregnant rats (n 
 4 to 11).
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of pregnant rats to values similar to those of nonpregnant rats
(Fig. 3D).
LKB1, an upstream activator of AMPK, was reduced in the
livers of pregnant rats at both the mRNA and protein levels
(37% and 42% lower, respectively, than that in nonpregnant
rats; P 	 0.05) (Fig. 3, E and F); the level of LKB1 phosphor-
ylation was also reduced in pregnant rats (51% lower than that
in nonpregnant rats; P 	 0.05) (Fig. 3G).
Biochemical profile of pregnant rats treated with AICAR.
Random glycemia was reduced in pregnant rats (18% lower
than that in nonpregnant rats; P 	 0.05), and this reduction
was abolished by treatment with AICAR (Fig. 4A). Circu-
lating TG were increased in pregnant rats irrespective of
AICAR treatment (98% and 84% higher, respectively, than
in nonpregnant rats; P 	 0.05) (Fig. 4B). The total circu-
lating cholesterol and HDL-C levels were similar among
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tinFig. 3. The AMPK pathway is down-regulated in the livers
of late-pregnant rats. Liver samples, both from pregnant
(gestational day 19) rats with or without 5-aminoimidazole-
4-carboxamide ribonucleotide (AICAR) treatment and from
age-paired nonpregnant rats, were processed for Western
blot detection of AMPK (A), phosphorylated AMPK (B),
acetyl-CoA carboxylase (ACC; C), and phosphorylated
ACC (D). Samples from nonpregnant and untreated preg-
nant rats were also used for Western blot detection of liver
kinase B1 (LKB1) (F) and phosphorylated LKB1 (G), and
for RNA extraction and qPCR analysis of the gene that
encodes LKB1, stk11 (E). Immunoblots were normalized by
-actin protein content. The results are shown as means 
SE. *P 	 0.05 vs. nonpregnant and pregnantAICAR
groups (n 
 6 to 14).
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nonpregnant, pregnant, and pregnantAICAR rats (Fig. 4,
C and D, respectively).
Changes in hepatic TG and glycogen content during
pregnancy are modulated by AICAR. The hepatic content of
phospholipids, free cholesterol, cholesterol esters, and free
fatty acids were similar among nonpregnant, pregnant and
pregnantAICAR rats (Figs. 5, A–D). However, we found a
reduction in hepatic TG in pregnant rats (19% lower than in
nonpregnant rats; P 	 0.05) that was blunted by AICAR
treatment (Fig. 5E).
The reduction in hepatic glycogen content observed in preg-
nant rats (48% lower than in nonpregnant rats; P 	 0.05) was
suppressed by AICAR treatment. Conversely, the increased
body and liver weight and liver-to-body weight ratio in preg-
nant rats (43%, 70%, and 20% higher, respectively, than in
nonpregnant rats; P 	 0.05) were not changed by AICAR
(Table 2).
Malic enzyme activity of pregnant rats is regulated by
AICAR in the liver but not in adipose tissue. Malic enzyme
activity was increased in the liver and in perigonadal and
subcutaneous adipose tissue of pregnant rats (28%, 253%, and
263% higher, respectively, than in nonpregnant rats; P	 0.05).
Treatment with AICAR restored malic enzyme activity in the
livers of pregnant rats to values similar to those found in
nonpregnant rats. The malic enzyme activity of adipose tissue
from pregnant rats was not affected by AICAR treatment
(Fig. 6A). Hepatic G6PDH activity in both pregnant and
pregnantAICAR rats was similar to that in nonpregnant rats.
Pregnancy was associated with an increase in G6PDH activity
in both perigonadal and subcutaneous adipose tissue (60% and
44% higher, respectively, than in nonpregnant rats; P 	 0.05),
which was unaffected by AICAR treatment (Fig. 6B). Of note,
differences in malic enzyme and G6PDH activity in the livers
of late-pregnant rats have been described previously (43).
Expression profile of genes related to lipid metabolism in the
livers of pregnant rats treated with AICAR. Previous research
has demonstrated that hepatic de novo lipogenesis and
VLDL-TG synthesis are increased in late pregnancy, whereas
hepatic TG content is decreased (29, 37). To investigate the
transcriptional profile underlying the reversal of the hepatic
TG content in pregnant rats following AICAR treatment, we
searched for changes in the expression of genes related to TG
synthesis and VLDL assembly (Fig. 7). The expression of fasn,
the gene that encodes fatty acid synthase, was upregulated in
late pregnancy (97% increase compared with nonpregnant rats;
P	 0.05) and was restored by AICAR treatment. Additionally,
dgat1 and dgat2 (which encode the two O-acyltransferase
isozymes) expression was increased in the livers of pregnant
rats (86% and 163% higher, respectively, than in nonpregnant
rats; P 	 0.05), and was also restored by AICAR treatment.
The expression of the gene encoding the microsomal triglyc-
eride transfer protein (mttp) was not altered either by the
pregnant state or by AICAR treatment. However, fatty acid
translocase (cd36) gene expression was upregulated both by
pregnancy (331%; P 	 0.05) and by AICAR treatment. In the
livers of pregnant rats treated with AICAR, cd36 expression
increased by an additional 68% (P 	 0.05). The expression of
the vesicle-trafficking protein SEC22b (sec22b) was also reg-
ulated by the pregnant state; sec22b expression was signifi-
cantly elevated in livers from untreated pregnant rats when
compared with the other two groups (270% higher than in
nonpregnant rats; P 	 0.05). Moreover, AICAR treatment
abolished the sec22b overexpression in pregnancy. Finally, we
analyzed the expression of apoB, the gene that encodes the rat
apolipoprotein B. We found that pregnancy upregulated apoB
expression (338% higher than the nonpregnant values; P 	
0.05) and that AICAR treatment restored apoB levels to values
similar to those observed in nonpregnant rats.
Pck1, the gene that encodes PEPCK, was evaluated as a
control of AICAR treatment (36). As expected, AICAR re-
duced pck1 expression (to 43% of that in pregnant rats; P 	
0.05).
DISCUSSION
Pieces of evidence point to a physiological regulation of
hepatic AMPK activity in response to changes in the circulat-
ing levels of various hormones (6, 7, 8, 15, 18, 60). For
example, the fasting- or physical exercise-induced increase of
the glucagon-insulin ratio causes AMPK activation in the liver
(7, 8, 18, 41). Overwhelming glucagon signaling promotes
hepatic glucose production and inhibits lipid biogenesis (re-
viewed in Ref. 26). Our present data show that maternal liver
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metabolism responds as expected to the reduced glucagon-
insulin ratio as follows: 1) decreased hepatic glucose produc-
tion after pyruvate load; 2) decreased AMPK activation; and 3)
increased de novo lipogenesis. Moreover, we provide several
additional pieces of evidence to support the hypothesis that the
AMPK pathway has a central role in the regulation of hepatic
energy metabolism during pregnancy.
In addition to the reduced glucagon-insulin ratio, other
pregnancy-related endocrine factors are theoretically able to
contribute to the hepatic adaptation to pregnancy. Estrogens,
for example, have been shown to reduce hepatic TG accumu-
lation in nonpregnant rodents, but the activation of estrogen
receptors was suggested to positively regulate AMPK activity
(59, 22). Moreover, in premenopausal women, the menstrual
cycle phase alone does not affect circulating TG or plasma
apoB100 (39). Thus, the isolated actions of sex steroids are
unlikely to completely account for the adaptation described
herein.
As STAT3 was described to bind to and repress the tran-
scription of g6pc (49), the increased STAT3 phosphorylation
in the liver during pregnancy might explain the decrease in
G6Pase expression. A myriad of signaling pathways, including
IL-6, IL-22, leptin, and growth hormone signaling, could
activate STAT3 in the liver (10, 50, 58). Among them, leptin
is increased during pregnancy and, by extension, is a putative
candidate to participate in this effect (5, 34). Also, considering
that the phosphorylation of CREB is a key step through which
glucagon stimulates G6Pase expression (53), we cannot rule
out that the decreased levels of pCREB might also contribute
to the reduced gluconeogenesis in the liver of pregnant rats.
Moreover, it has been recently demonstrated that the activation
of AMPK inhibited STAT3 phosphorylation in both murine
hepatocytes and HepG2 cell line (17, 35, 42), indicating that
the increase in STAT3 phosphorylation found in the liver of
late-pregnant rats could be due to the reduced AMPK activa-
tion.
The activity of AMPK is regulated by direct allosteric
activation, as well as the reversible phosphorylation of Thr-172
within the catalytic subunit by at least the following two
upstream kinases: 1) the tumor suppressor LKB1/SKT11 (ser-
ine/threonine kinase-11) and 2) CaMKK (Ca2/calmodulin-
dependent protein kinase kinase-). In the liver, LKB1 plays a
crucial role in activating AMPK and in controlling glucose and
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Fig. 5. Hepatic lipid profile of nonpregnant rats, untreated
pregnant rats, and pregnant rats treated with AICAR. Lipids
were extracted and subjected to thin-layer chromatography.
The plates were scanned to evaluate the hepatic content of
phospholipids (A), cholesterol (B), cholesterol esters (C), free
fatty acids (D), and TG (E). The values were expressed as
arbitrary units. Experiments were conducted on gestational
day 19. The results are shown as the means  SE. *P 	 0.05
vs. nonpregnant and pregnantAICAR rats (n 
 5 to 10).
Table 2. Body and liver weights, liver-to-body weight,
and hepatic glycogen content in nonpregnant, pregnant,
and pregnantAICAR rats
Nonpregnant Pregnant PregnantAICAR
Body weight, g 245.3  8.7 (4) 350.7 9.9* (4) 376.7 6.8* (4)
Liver weight, g 7.4  0.1 (4) 12.6 0.2* (4) 14.7 0.7* (4)
Liver-to-body
weight ratio 3.0  0.2 (4) 3.6 0.1* (4) 3.9 0.2* (4)
Hepatic
glycogen, % 2.2  0.2 (10) 1.2 0.1*# (8) 2.0 0.1 (5)
Nonpregnant, pregnant and pregnantAICAR rats were weighed and eu-
thanized. Livers were collected, weighted, and processed for glycogen deter-
mination. Data are presented as the means  SE (n). *P 	 0.05 vs. nonpreg-
nant; #P 	 0.05 vs. pregnantAICAR.
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lipid metabolism (30, 55). Accordingly, our data show that
LKB1 expression and phosphorylation, as well as its down-
stream target AMPK, were downregulated in the livers of
late-pregnant rats. Moreover, the phosphorylation of ACC, a
rate-limiting enzyme of fatty acid synthesis that is phosphor-
ylated and inactivated by AMPK (27), was also reduced, which
suggests a redirection of the pyruvate flux to the lipogenic
rather than the gluconeogenic metabolic pathway. Evidence for
this theory is given by the data from the hepatic perfusion with
pyruvate and the pyruvate tolerance test.
Additionally, the upregulation of malic enzyme activity
reported herein suggests increased hepatic synthesis of TG
during pregnancy. Malic enzyme is a key lipogenic enzyme
that catalyzes malate decarboxylation and generates NADPH
to de novo fatty acid synthesis by FASN (1). Thus, we
hypothesize that the depletion of hepatic TG content observed
in pregnant rats is due to the increased VLDL secretion rather
than the reduced de novo synthesis of fatty acids. Our data also
suggest that this hepatic adaptation to pregnancy, which is
characterized by increased fatty acid synthesis and VLDL
secretion, is dependent upon the downregulation of AMPK in
the liver, given that AICAR treatment normalizes hepatic malic
enzyme activity and TG content. We cannot, however, exclude
the participation of additional signaling pathways in this adap-
tation since AICAR is not a highly specific AMPK activator.
Maternal hypertriglyceridemia, which is one of the most
striking physiological changes to occur in late pregnancy,
favors the use of lipids by key maternal tissues and is likely to
contribute to glucose sparing for fetal accretion. When com-
pared with virgin rats, a higher rate of maternal de novo liver
lipogenesis was observed at the 20th day of pregnancy (37).
Importantly, pregnancy-related hypertriglyceridemia is a con-
sequence of both the increase in hepatic VLDL production and
the reduced TG removal from the bloodstream due to the
downregulation of lipoprotein lipase activity in adipose and
muscle tissues (29). This fact most likely explains why AMPK
activation with AICAR restores hepatic TG without affecting
the levels of circulating TG. As we understand, the reduced TG
removal from the bloodstream during pregnancy acts as the
limiting step that determines fluctuations in circulating lipids.
In accordance with this hypothesis, it is noteworthy that adi-
pose tissue lipoprotein lipase activity is insensitive to AICAR-
induced AMPK activation (46). Notably, the rats that were
used for biochemical measurements were under nonfasting
conditions. Therefore, intestinal chylomicron production needs
to be considered as a relevant source of circulating TG.
Our data indicating that the increased levels of malic enzyme
activity in the adipose tissue of pregnant rats are not affected
by AICAR further suggests that AMPK plays a specific role in
the energy metabolism adaptation of the liver to pregnancy. Of
note, considering that lipoprotein lipase activity in adipose
tissue is reduced (29), the increased activity of malic enzyme in
adipose tissue suggests that de novo lipogenesis accounts for
the higher adiposity of pregnant rats. In fact, it has been
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Fig. 6. Activity of enzymes related to the lipogenic pathway
in the liver and adipose tissue of nonpregnant and pregnant
rats treated or not with AICAR. Fragments of the liver and the
perigonadal and subcutaneous adipose tissue were removed
and processed for malic enzyme (A) and G6PDH (B) activi-
ties. Experiments were conducted on gestational day 19. The
results are shown as the means  SE. *P 	 0.05 vs.
nonpregnant rats (n 
 4 to 6).
R1153REGULATION OF MATERNAL LIVER METABOLISM BY AMPK
AJP-Regul Integr Comp Physiol • doi:10.1152/ajpregu.00513.2013 • www.ajpregu.org
demonstrated that lipogenesis was greater in adipose tissue
from 19-day pregnant rats than nonpregnant rats (31).
Our data showing increased hepatic ACC and malic enzyme
activities in conjunction with the increased expression of the
fasn and dgat genes provide a molecular network that is able to
support the adaptation of the liver to pregnancy. Indeed,
previous research has observed reduced fasn and dgat2 expres-
sion and reduced cellular content of FASN upon AMPK
activation (47, 61). Given that we observed a restoration of
hepatic TG content, as well as fasn and dgat expression, after
increasing AMPK activity with AICAR treatment in pregnant
rats, we next evaluated the expression of genes related to fatty
acid transport and VLDL assembly.
The vesicle-trafficking protein homolog B Sec22b is one of
the components of the SNARE (soluble N-ethylmaleimide-
sensitive factor-attachment protein receptor) complex that is
required for the delivery of VLDL-transport vesicles to the
Golgi (56). Although the exportation of nascent VLDL parti-
cles to the Golgi is considered a physiologically highly regu-
lated event, to our knowledge, there have been no previous
demonstrations of the modulation of sec22b expression in a
physiological model of an increased hepatic metabolic state.
We observed that hepatic sec22b is upregulated in late preg-
nancy in an AMPK-dependent fashion, and treatment with
AICAR restored its levels to those of a nonpregnant state.
Likewise, the expression of apoB, the gene that encodes the
essential structural VLDL protein apoB (the rat counterpart of
the human apoB100), paralleled the changes in sec22b expres-
sion. Interestingly, proteomic studies have demonstrated that
Sec22b binds to apoB100 at the ER level (48, 51). The same
expression pattern of these two main proteins associated with
nascent VLDL showed herein points to a mechanistic role for
AMPK in VLDL biogenesis, intracellular trafficking, and se-
cretion from the liver.
Consistent with the increased TG synthesis and VLDL
secretion already described in late pregnancy (29, 37), our data
show that the expression of fatty acid translocase (FAT)/
CD36—the most important protein implicated in fatty acid
uptake by skeletal muscle cells, cardiomyocytes, and adi-
pocytes (9)—is increased in the livers of pregnant rats. Cd36
expression is very low in healthy livers, suggesting that fatty
acid uptake is FAT/CD36-independent under physiological
conditions (38). However, in cardiac myocytes and perfused
hearts, the prolonged AMPK activation by AICAR treatment
increased the expression and the plasmalemmal content of
FAT/CD36 (20). In accordance with the observations in heart
tissue, we found that AICAR treatment increased hepatic cd36
expression.
Notably, the above scenario, although consistent with the
hypothesis of the central role of the AMPK pathway in the
regulation of maternal hepatic fuel metabolism, requires fur-
ther investigation. For example, we do not have data to explain
the unexpectedly high expression of cd36 in the livers of
pregnant rats, even in the presence of low AMPK activity. As
of now, we can only speculate that a combination of factors
that constitute the complex internal milieu of pregnancy may
be inducing the hepatic phenotype described herein. For ex-
ample, the high insulin levels of late pregnancy could coun-
teract the reduced AMPK activity and increase hepatic cd36
expression (12).
Perspectives and Significance
Our data support the premise that AMPK participates in the
regulation of maternal hepatic lipid metabolism. We suggest
that the reduced hepatic AMPK activity of late pregnancy is
likely to result in an increase in hepatic fatty acid synthesis that
parallels a robust upregulation of VLDL assembly and secre-
tion, thus manifesting as the reduced hepatic content of TG.
This intracellular pathway is likely to be specific for the liver
because the lipogenic activity of the adipose tissue was insen-
sitive to AICAR. The transcriptional profile downstream of
AMPK most likely encompasses the regulation of hepatic dgat,
fasn, sec22b, and apoB expression.
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